CV:NGEN NervGen Pharma Corp.

NervGen Pharma Corp., a biotech company, discovers and develops treatments for patients suffering from medical conditions related to nerve damage. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol NGENF.

2.94 CAD
As of 12/03/2021


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  Canada
IPO date:  01/01/1900
Stock exchange:    TSX Venture Exchange
Exchange country:   Canada
Market cap:   128,890,919 CAD
Current dividend yield:   0.00%
CUSIP:    
ISIN:        CA64082X2032
Sedol:      

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy